Results 111 to 120 of about 1,181 (167)

Abschätzung der Arzneimittelausgaben der Gesetzlichen Krankenversicherung 2014 und 2015: Gutachterliche Stellungnahme für den Verband forschender Arzneimittelhersteller e. V. (vfa) [PDF]

, 2013
Greß, Stefan, Wasem, Jürgen
core  

New drugs and their performance 10 years after approval: a systematic analysis. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Manfouo B, Seifert R.
europepmc   +1 more source

Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action. [PDF]

Curr Oncol
Sehdev S, Gotfrit J, Elias M, Stein BD.
europepmc   +1 more source

Towards a Unified European View of Clinical Evidence: What 'Health Technology Assessment Organizations' Can Learn from Regulatory Experience. [PDF]

J Mark Access Health Policy
Broich K, Löbker W.
europepmc   +1 more source

PTX-loaded, polysorbate 80-functionalized brain-targeting pullulan nanoparticles for drug delivery. [PDF]

Front Pharmacol
Yuan H, Han L, Deng H, Tan Y, Yang Y, Liu Y, Ying J, Fang M, Wei H, Tao Z.   +9 more
europepmc   +1 more source

National guidelines for gastric cancer: redundant or needed? [PDF]

Gastric Cancer
Lordick F, Wörmann B.
europepmc   +1 more source

Healthcare effects and evidence robustness of reimbursable digital health applications in Germany: a systematic review. [PDF]

NPJ Digit Med
Sippli K, Deckert S, Schmitt J, Scheibe M.   +3 more
europepmc   +1 more source

Cost-utility analysis of ¹⁷⁷Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany. [PDF]

Eur J Nucl Med Mol Imaging
Brinkmann C, Baum RP, Stargardt T.
europepmc   +1 more source